CD8A and metastatic neoplasm: In addition, we also previously reported that in mouse models of metastatic disease, MBTA treatment significantly increased the quantity of CD8+ cytotoxic T lymphocytes, with a sustained response on second challenge with subcutaneously injected tumor cells [23].